In a milestone for complement-mediated diseases, the first C3-targeting modality, pegcetacoplan, a derivative of compstatin, was approved in 2021 for the treatment of PNH, establishing C3 as a generally safe and viable therapeutic target for this condition [29]. The gene discussed is C3; the disease is paroxysmal nocturnal hemoglobinuria.